Opexa Therapeutics (OPXA) Announces Pricing of Public Offering of Common Stock
8/8/2013 9:52:29 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the pricing of an underwritten public offering of 12 million shares of its common stock at a price to the public of $1.50 per share. The gross proceeds to Opexa from this offering are expected to be approximately $18 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Opexa. Opexa has also granted the underwriters a 30-day option to purchase up to an additional 1.8 million shares of common stock to cover over-allotments, if any. The offering is expected to close on or about August 13, 2013, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
comments powered by